Compare BG & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BG | CRL |
|---|---|---|
| Founded | 1818 | 1947 |
| Country | United States | United States |
| Employees | N/A | 19700 |
| Industry | Packaged Foods | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.1B | 16.2B |
| IPO Year | 2023 | 1999 |
| Metric | BG | CRL |
|---|---|---|
| Price | $99.55 | $339.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 17 |
| Target Price | $139.22 | ★ $318.87 |
| AVG Volume (30 Days) | ★ 1.5M | 1.2M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 5.45 | ★ 6.48 |
| Revenue | ★ $70,329,000,000.00 | $1,857,601,000.00 |
| Revenue This Year | $33.73 | N/A |
| Revenue Next Year | $1.94 | $2.53 |
| P/E Ratio | ★ $17.80 | $50.35 |
| Revenue Growth | N/A | ★ 10.48 |
| 52 Week Low | $88.24 | $146.20 |
| 52 Week High | $134.87 | $379.63 |
| Indicator | BG | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 43.05 | 53.12 |
| Support Level | N/A | $151.03 |
| Resistance Level | $126.62 | $379.63 |
| Average True Range (ATR) | 2.92 | 19.27 |
| MACD | 0.10 | -3.83 |
| Stochastic Oscillator | 63.02 | 41.54 |
Bunge Global SA is an agribusiness solutions company, connecting farmers to consumers and delivering essential food, feed and fuel to the globe. The company segments include Soybean Processing and Refining; Softseed Processing and Refining; Other Oilseeds Processing and Refining; Grain Merchandising and Milling; and Corporate and Other. It generates maximum revenue from the Soybean Processing and Refining segment, which includes integrated business principally involved in the purchase, storage, transportation, processing, distribution, refining, marketing, and sale of soybeans and soybean related products, as well as biodiesel and fertilizer production and distribution. Geographically, the company operates in United States, Switzerland, Netherlands, and Rest of the World.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.